The generic version, Insulin Lispro, contains the same molecule as Humalog, a rapid-acting insulin. It is indicated to improve glycemic control in adults and children with diabetes mellitus.
The Company will work with supply chain partners to introduce Insulin Lispro to pharmacies as soon as possible. The authorized generic will be made available through ImClone Systems, a Lilly subsidiary. Humalog will still be available for patients who wish to continue using the brand product.
“We’re eager to bring forward a low-priced rapid-acting insulin,” stated David A. Ricks, Lilly’s chairman and CEO. “For people with diabetes, a lower-priced insulin can serve as a bridge that addresses gaps in the system until a more sustainable model is achieved.”
Insulin Lispro 100 Units/mL will be supplied in single vials ($137.35) or 5-count KwikPens ($265.20). The Lilly Diabetes Solutions Center is available to patients to learn more about insulin affordability.
For more information call (833) 808-1234 or visit Lilly.com.
This article originally appeared on MPR